tetano
Editor, Senior Moderator
Eur Rev Med Pharmacol Sci
. 2020 May;24(10):5783-5787.
doi: 10.26355/eurrev_202005_21372.
Tocilizumab in the Treatment of a Critical COVID-19 Patient: A Case Report
L Wang[SUP] 1 [/SUP], X Peng, Z-H Wang, J Cai, F-C Zhou
Affiliations
Abstract
In December 2019, Coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread throughout China and the rest of the world. COVID-19 is currently a global pandemic. There are cytokine storms in severe COVID-19 patients. Interleukin-6 plays an important role in cytokine storm. Tocilizumab is a blocker of interleukin-6 receptor, which is likely to become an effective drug for patients with severe COVID-19. Here, we reported a case in which tocilizumab was effective for a critical COVID-19 patient.
. 2020 May;24(10):5783-5787.
doi: 10.26355/eurrev_202005_21372.
Tocilizumab in the Treatment of a Critical COVID-19 Patient: A Case Report
L Wang[SUP] 1 [/SUP], X Peng, Z-H Wang, J Cai, F-C Zhou
Affiliations
- PMID: 32495916
- DOI: 10.26355/eurrev_202005_21372
Abstract
In December 2019, Coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread throughout China and the rest of the world. COVID-19 is currently a global pandemic. There are cytokine storms in severe COVID-19 patients. Interleukin-6 plays an important role in cytokine storm. Tocilizumab is a blocker of interleukin-6 receptor, which is likely to become an effective drug for patients with severe COVID-19. Here, we reported a case in which tocilizumab was effective for a critical COVID-19 patient.